Switch theme
Sign up to access all valuation multiples
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics.
1981
11.1K+
LTM Revenue $915M
LTM EBITDA $172M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Emcure Pharmaceuticals has a last 12-month revenue of $915M and a last 12-month EBITDA of $172M.
In the most recent fiscal year, Emcure Pharmaceuticals achieved revenue of $764M and an EBITDA of $147M.
Emcure Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Emcure Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $689M | $764M | XXX | XXX | XXX |
| Gross Profit | $410M | $426M | XXX | XXX | XXX |
| Gross Margin | 60% | 56% | XXX | XXX | XXX |
| EBITDA | $139M | $147M | XXX | XXX | XXX |
| EBITDA Margin | 20% | 19% | XXX | XXX | XXX |
| Net Profit | $76.9M | $61.8M | XXX | XXX | XXX |
| Net Margin | 11% | 8% | XXX | XXX | XXX |
| Net Debt | $233M | $248M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Emcure Pharmaceuticals's stock price is INR 919 (or $11).
Emcure Pharmaceuticals has current market cap of INR 174B (or $2.0B), and EV of INR 183B (or $2.1B).
See Emcure Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $2.0B | XXX | XXX | XXX | XXX | $0.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Emcure Pharmaceuticals has market cap of $2.0B and EV of $2.1B.
Emcure Pharmaceuticals's trades at 2.3x LTM EV/Revenue multiple, and 12.3x LTM EBITDA.
Analysts estimate Emcure Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Emcure Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 12.9x | XXX | XXX | XXX |
| P/E | 27.0x | XXX | XXX | XXX |
| P/E/Growth | 1.1x | XXX | XXX | XXX |
| EV/FCF | 37.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEmcure Pharmaceuticals's NTM/LTM revenue growth is 11%
Emcure Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $33K for the same period.
Over next 12 months, Emcure Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Emcure Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Emcure Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 30% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $33K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 48% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Emcure Pharmaceuticals acquired XXX companies to date.
Last acquisition by Emcure Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Emcure Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Emcure Pharmaceuticals founded? | Emcure Pharmaceuticals was founded in 1981. |
| Where is Emcure Pharmaceuticals headquartered? | Emcure Pharmaceuticals is headquartered in India. |
| How many employees does Emcure Pharmaceuticals have? | As of today, Emcure Pharmaceuticals has 11.1K+ employees. |
| Is Emcure Pharmaceuticals publicy listed? | Yes, Emcure Pharmaceuticals is a public company listed on BOM. |
| What is the stock symbol of Emcure Pharmaceuticals? | Emcure Pharmaceuticals trades under 544210 ticker. |
| When did Emcure Pharmaceuticals go public? | Emcure Pharmaceuticals went public in 2024. |
| Who are competitors of Emcure Pharmaceuticals? | Similar companies to Emcure Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Emcure Pharmaceuticals? | Emcure Pharmaceuticals's current market cap is $2.0B |
| What is the current revenue of Emcure Pharmaceuticals? | Emcure Pharmaceuticals's last 12-month revenue is $915M. |
| What is the current EBITDA of Emcure Pharmaceuticals? | Emcure Pharmaceuticals's last 12-month EBITDA is $172M. |
| What is the current EV/Revenue multiple of Emcure Pharmaceuticals? | Current revenue multiple of Emcure Pharmaceuticals is 2.3x. |
| What is the current EV/EBITDA multiple of Emcure Pharmaceuticals? | Current EBITDA multiple of Emcure Pharmaceuticals is 12.3x. |
| What is the current revenue growth of Emcure Pharmaceuticals? | Emcure Pharmaceuticals revenue growth between 2023 and 2024 was 11%. |
| Is Emcure Pharmaceuticals profitable? | Yes, Emcure Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
